Search

Your search keyword '"Daniel Noujaim"' showing total 6 results
Start Over Author "Daniel Noujaim"
6 results on '"Daniel Noujaim"'

1. Contributors

Author

Joachim M. Baehring, Dhiego C.A. Bastos, Richard Beegle, Wenya Linda Bi, Kyle M. Blackburn, Deborah T. Blumenthal, Eric C. Bourekas, Joseph A. Bovi, Nicole Petrovich Brennan, Alyssa Brown, Joshua A. Budhu, L. Burt Nabors, Marc Bussiere, Arnab Chakravarti, Marc C. Chamberlain, Samuel T. Chao, Paul H. Chapman, Clark C. Chen, Susan Chi, Serah Choi, Gregory A. Christoforidis, Jennifer L. Clarke, Diogo Goulart Corrêa, Luiz Celso Hygino da Cruz, Maria Diaz, Karan S. Dixit, Sean Dodson, Ryan M. Edwards, Shehanaz Ellika, Moataz Ellithi, Aladine A. Elsamadicy, Peter E. Fecci, Mark A. Ferrante, Nicholas C. Ferraro, Melvin Field, Ryan Fisicaro, Ekokobe Fonkem, Robert K. Fulbright, Elizabeth R. Gerstner, Alexandra J. Golby, Carlos R. Goulart, Jeffrey P. Guenette, Michael Guiou, Nilendu Gupta, Ahmed Halima, Angel L. Hatef, Johannes T. Heverhagen, Andrei Holodny, Tudor Hesketh Hughes, David Huie, Ahmet Turan Ilica, K. Ina Ly, Michael E. Ivan, Rajan Jain, Jens Johansson, Michele H. Johnson, Ferenc A. Jolesz, Edward W. Jung, Alayar Kangarlu, Arash Kardan, Philipp Karschnia, Gurvinder Kaur, Marie Foley Kijewski, Jinsuh Kim, Madison Kocher, Ricardo J. Komotar, George Krol, Sylvia C. Kurz, Michael Kwofie, Joshua Lantos, Eudocia Quant Lee, Emilie Le Rhun, Emily C. Lerner, Benjamin P. Liu, Simon S. Lo, Mina Lobbous, Jay S. Loeffler, Stephen R. Lowe, Evan Luther, Stephan E. Maier, Lonika Majithia, Mina S. Makary, Tobias A. Mattei, Zachary S. Mayo, Ehud Mendel, Tom Mikkelsen, Pedro C. Miranda, Bradford A. Moffat, Erin S. Murphy, John Vincent Murray, Raymond F. Muzic, Prashant Nagpal, Michelle J. Naidich, Herbert B. Newton, Erik B. Nine, Michal Nisnboym, Daniel Noujaim, Nancy Ann Oberheim Bush, Olutayo Olubiyi, Sacit Bulent Omay, Nina A. Paleologos, Kunal S. Patel, Isabela Pena Pino, Tina Young Poussaint, Sanjay P. Prabhu, Lei Qin, Jinrong Qu, Karim Rebeiz, Haricharan Reddy, Benjamin C. Reeves, Lisa R. Rogers, Martin Satter, Mithun G. Sattur, Kathleen M. Schmainda, Mana Shams, Sara Shams, V. Michelle Silvera, Andrew Sloan, H. Wayne Slone, James Snyder, Daniel K. Sodickson, Aaron D. Sodickson, Lilja Bjork Solnes, Maria Vittoria Spampinato, Ethan S. Srinivasan, John H. Suh, Yanping Sun, Nicholas A. Sutton, Ramya Tadipatri, Suzanne Tharin, Ryan Thompson, Tia H. Turner, Eugene J. Vaios, Steven Vernino, Michael A. Vogelbaum, Steve Walston, Jeffrey Waltz, Michael A. Weicker, D. Bradley Welling, Patrick Y. Wen, Cornelia Wenger, Max Wintermark, Eric T. Wong, Edward Yang, Randy Yeh, Onur Yildirim, Geoffrey S. Young, Robert J. Young, Rujman U. Zaman, and Alicia M. Zukas

Published
2022

2. COVID-19-associated Acute Hemorrhagic Necrotizing Encephalopathy: Imaging Features

Author

Neo Poyiadji, Michael Stone, Brent Griffith, Gassan Shahin, Suresh C. Patel, and Daniel Noujaim

Subjects
2019-20 coronavirus outbreak, Pathology, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Pneumonia, Viral, Betacoronavirus, X ray computed, medicine, Humans, Radiology, Nuclear Medicine and imaging, Necrotizing encephalopathy, Letters to the Editor, Pandemics, medicine.diagnostic_test, business.industry, SARS-CoV-2, Brain, COVID-19, Magnetic resonance imaging, Middle Aged, medicine.disease, Magnetic Resonance Imaging, Leukoencephalitis, Acute Hemorrhagic, Pneumonia, Tomography x ray computed, Female, business, Coronavirus Infections, Tomography, X-Ray Computed
Published
2020

3. Time Sensitivity: A Parameter Reflecting Tumor Metabolic Kinetics by Variable Dual-Time F-18 FDG PET Imaging

Author

Daniel Noujaim, Ching-yee Oliver Wong, Cheng-yi S. Cheng, Chih-Yung Chang, Hungsen F. Fu, Ishani Dalal, Wen-Sheng Huang, Conrad E. Nagle, and Joseph A. Thie

Subjects
Adult, Blood Glucose, Male, Cancer Research, Time Factors, Standardized uptake value, Fluorodeoxyglucose positron emission tomography, Fluorodeoxyglucose F18, Metabolic kinetics, Linear regression, medicine, Humans, Radiology, Nuclear Medicine and imaging, Aged, business.industry, Time sensitivity, Middle Aged, F 18 fdg pet, medicine.disease, Primary tumor, Oncology, Head and Neck Neoplasms, Positron-Emission Tomography, Linear Models, Female, Radiopharmaceuticals, Tomography, X-Ray Computed, Nuclear medicine, business, Algorithms, Brain metastasis
Abstract

The aim of this study was to define and investigate the time sensitivity of tumors by variable dual-time fluorodeoxyglucose positron emission tomography (FDG PET). Variable dual-time (t) protocol (P) FDG PET–computed tomography (CT) scans from 40 patients with pathologically proven head and neck tumors without brain metastasis were analyzed. The first protocol (P.I) consisted of 26 patients with early (E) and delayed (D) PET–CT obtained at 106 ± 15 and 135 ± 16 min after injection of 16.3 ± 1.9 mCi FDG. The second protocol (P.II) recruited 14 patients with E- and D-PET performed at 54 ± 13 and 151 ± 28 min after injection of 9.6 ± 1.7 mCi FDG. The maximum standardized uptake values (SUVs) were measured in the primary tumor (CA1) and the cerebellum (CBL). The time sensitivity (S) was defined as d{ln(SUV)}/d{ln(t)} and its value was obtained by linear regression of ln(D-SUV/E-SUV) vs ln(t D/t E). Patients with cerebellar variations greater than 30% in SUV between E- and D-PET was excluded from the analysis. Two patients from P.I were excluded due to wide cerebellar SUV variations. D-SUV were significantly higher than E-SUV in CA1 for both P.I (18.9 ± 6.9 vs 14.8 ± 5.6, p

Published
2009

4. Susceptibility-Weighted Imaging Diagnosis of Cerebral Fat Embolism

Author

Daniel Noujaim, Joseph D. Burns, and Brian J. Scott

Subjects
medicine.medical_specialty, medicine.diagnostic_test, business.industry, MEDLINE, Magnetic resonance imaging, Images in Clinical Neurology, 030204 cardiovascular system & hematology, medicine.disease, 030218 nuclear medicine & medical imaging, 03 medical and health sciences, 0302 clinical medicine, Text mining, Susceptibility weighted imaging, Medicine, Neurology (clinical), Radiology, Fat embolism, business
Published
2016

5. N-Myc and Bcl-2 coexpression induces MMP-2 secretion and activation in human neuroblastoma cells

Author

Cynthia M. van Golen, Eva L. Feldman, Alyssa R Grauman, Kenneth L. van Golen, and Daniel Noujaim

Subjects
Cancer Research, Cell division, Blotting, Western, Matrix metalloproteinase, Biology, medicine.disease_cause, Proto-Oncogene Proteins c-myc, Neuroblastoma, Downregulation and upregulation, Genetics, medicine, Tumor Cells, Cultured, Humans, Secretion, Neoplasm Invasiveness, RNA, Messenger, Molecular Biology, Regulation of gene expression, Tissue Inhibitor of Metalloproteinase-2, medicine.disease, Up-Regulation, Enzyme Activation, Gene Expression Regulation, Neoplastic, Proto-Oncogene Proteins c-bcl-2, Cancer research, Matrix Metalloproteinase 2, Carcinogenesis, N-Myc, Cell Division
Abstract

Neuroblastoma is a peripheral nervous system tumor that accounts for 8-10% of all solid childhood tumors. N-Myc is the most reliable prognostic indicator for neuroblastoma. Bcl-2 is detected in 40-60% of primary neuroblastoma tumors and demonstrates anti-apoptotic action by conferring resistance to chemotherapy and radiation treatment. In neuroblastoma cell lines, the coexpression of N-Myc and Bcl-2 leads to increased tumorigenic properties. Matrix metalloproteinases (MMPs) are endopeptidases that degrade a wide range of basement membrane components, a process important for tumor invasion. This study investigates the effect of N-Myc and Bcl-2 on MMP expression and activation. MMP-2 expression and secretion are increased in SHEP neuroblastoma cells expressing Bcl-2 alone (SHEP/Bcl-2 cells) or both N-Myc and Bcl-2 (SHEP/N-Myc/Bcl-2 cells). MMP-2 activity is increased in the SHEP/N-Myc/Bcl-2 cells yet remains unchanged in SHEP/Bcl-2 cells. TIMP-2 expression is high in SHEP/Bcl-2 cells, which likely inhibits MMP-2 activity, and absent in SHEP/N-Myc/Bcl-2 cells, allowing MMP-2 activity. Invasion is increased in SHEP/N-Myc/Bcl-2 cells and prevented by the use of a pharmacologic MMP-2 inhibitor. These data imply that N-Myc and Bcl-2 cooperate to increase the expression, secretion, and activation of MMP-2, which likely leads to a more tumorigenic phenotype due to increased MMP-2 mediated invasion.

Published
2001

6. Time Sensitivity: A Parameter Reflecting Tumor Metabolic Kinetics by Variable Dual-Time F-18 FDG PET Imaging.

Author

Ching-yee Wong, Daniel Noujaim, Hungsen Fu, Wen-sheng Huang, Cheng-yi Cheng, Joseph Thie, Ishani Dalal, Chih-yung Chang, and Conrad Nagle

Subjects
*HEAD tumors, *MEDICAL imaging systems, *METABOLISM, *POSITRON emission tomography, *NECK tumors, *METASTASIS, *REGRESSION analysis
Abstract

Abstract Objectives  The aim of this study was to define and investigate the time sensitivity of tumors by variable dual-time fluorodeoxyglucose positron emission tomography (FDG PET). Methods  Variable dual-time (t) protocol (P) FDG PET–computed tomography (CT) scans from 40 patients with pathologically proven head and neck tumors without brain metastasis were analyzed. The first protocol (P.I) consisted of 26 patients with early (E) and delayed (D) PET–CT obtained at 106 ± 15 and 135 ± 16 min after injection of 16.3 ± 1.9 mCi FDG. The second protocol (P.II) recruited 14 patients with E- and D-PET performed at 54 ± 13 and 151 ± 28 min after injection of 9.6 ± 1.7 mCi FDG. The maximum standardized uptake values (SUVs) were measured in the primary tumor (CA1) and the cerebellum (CBL). The time sensitivity (S) was defined as d{ln(SUV)}/d{ln(t)} and its value was obtained by linear regression of ln(D-SUV/E-SUV) vs ln(t D/t E). Patients with cerebellar variations greater than 30% in SUV between E- and D-PET was excluded from the analysis. Results  Two patients from P.I were excluded due to wide cerebellar SUV variations. D-SUV were significantly higher than E-SUV in CA1 for both P.I (18.9 ± 6.9 vs 14.8 ± 5.6, p vs 9.7 ± 6.9, p = 0.013). The S values for CA1 in P.I and P.II were 0.67 and 0.17, respectively. The D-SUV were also higher than E-SUV in CBL for both P.I (12.5 ± 1.6 vs 11.6 ± 1.6, p vs 7.0 ± 1.6, p = 0.008). The S values for CBL in P.I and P.II were 0.47 and 0.04, respectively, which were over 1.4-fold smaller than that of CA1, suggesting fundamental kinetic differences between CA1 and CBL. Conclusions  The time sensitivity factor reflects another kinetic parameter of tumor metabolism besides SUV when using variable dual-time FDG PET. It offers another useful diagnostic tool in optimizing choices of dual-time protocols for oncologic PET–CT and in reducing SUV variations due to time interval differences with corrections using S. [ABSTRACT FROM AUTHOR]

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results